What is it about?
Frequency of targetable mutation in patients with cancer.
Featured Image
Why is it important?
It helps with estimating the total number of patients which may be helped by vemurafenib or similar therapy.
Perspectives
Important companion study to vemurafenib basket trial published in NEJM, Hyman, Puzanov et al., 2015
Professor Igor Puzanov
Roswell Park Cancer Institute
Read the Original
This page is a summary of: BRAFV600 mutations in solid tumors, other than metastatic melanoma and papillary thyroid cancer, or multiple myeloma: a screening study, OncoTargets and Therapy, February 2017, Dove Medical Press,
DOI: 10.2147/ott.s120440.
You can read the full text:
Contributors
The following have contributed to this page
